← Back to all trials
Completed
NCT04325217
Post-marketing Surveillance on Long Term Use of Ofev Capsules in Systemic Scleroderma Associated Interstitial Lung Disease (SSc-ILD) in Japan
Conditions: Lung Diseases, Interstitial
Sex: All
Healthy volunteers: No
Enrollment: 586
Sponsor: Boehringer Ingelheim
Location: Nippon Boehringer Ingelheim Co., Ltd. Tokyo
Summary
The primary objective is to confirm the incidence of adverse drug reactions (focus on gastrointestinal symptoms including diarrhoea and nausea) to Ofev Capsules seen in clinical trials with real world data generated in patients with SSc-ILD.
Eligibility Criteria
Inclusion Criteria:
* Patients in Japan with SSc-ILD who are prescribed with Ofev Capsules and have never been treated with Ofev Capsules before enrolment will be included.
Exclusion Criteria:
* None.
Source: ClinicalTrials.gov (NCT04325217). StuddyBuddy aggregates publicly available trial information.
